- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT02009644
Клиническое исследование стент-графта Treovance у пациентов с аневризмами брюшной аорты
Клиническое исследование II фазы безопасности и эффективности стент-графта Treovance с системой доставки Navitel у пациентов с инфраренальными аневризмами брюшной аорты
The purpose of this clinical trial is to assess and evaluate the safety and efficacy of the Treovance Stent-Graft with Navitel Delivery System in subjects with Abdominal Aortic Aneurysms (AAA).
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
This is a phase II, multi-center, non-blinded, non-randomized study of treatment with the Treovance Stent-Graft in subjects with abdominal aortic aneurysms. The study will include 150 subjects treated with the Treovance Stent-Graft at a maximum of 30 investigational sites. Upon completion of enrollment of150 subjects, an additional 50 subjects may be treated with the Treovance Stent-Graft at the 30 investigative sites participating in the trial. These additional subjects will follow the same study schedule, and data from these patients may be used to supplement the pivotal trial data. There will be no prospective control group. Subjects diagnosed with infrarenal abdominal aortic aneurysms enrolled in the trial will be treated with the Treovance Stent-Graft with Navitel Delivery System. Pre-procedure baseline data will be gathered, as well as post-procedure assessments prior to hospital discharge and 30 days, 6 months, and 12 months post-implantation. In addition, annual follow-up visits out to 5 years will be conducted. Subjects with fracture(s) confirmed by the Core Lab within the first 5 years will be followed for an additional 5 years, for a total of 10 years post-implantation.
The primary goal of this study is to gather safety and effectiveness data on the Treovance device. A maximum of 150 endovascular subjects will be required to fulfill the U.S. Phase II requirements. The data from this study will be submitted to the FDA and used to support approval in the U.S.
There are two primary objectives, efficacy and safety of the Treovance Stent-Graft in subjects with infrarenal aortic aneurysms:
- Primary Efficacy will be evaluated by successful aneurysm treatment 12 months post-implant
- Primary Safety will be assessed by composite major adverse event (MAE) rate at 30-days
Secondary objectives involve assessment of major device-related events and major morbidity.
Тип исследования
Регистрация (Действительный)
Фаза
- Непригодный
Контакты и местонахождение
Места учебы
-
-
Alabama
-
Birmingham, Alabama, Соединенные Штаты, 35294
- University of Alabama-Birmingham
-
-
Arizona
-
Phoenix, Arizona, Соединенные Штаты, 85006
- Arizona Heart Institute
-
-
Connecticut
-
Danbury, Connecticut, Соединенные Штаты, 06810
- Danbury Hospital
-
-
Florida
-
Boca Raton, Florida, Соединенные Штаты, 33486
- Lynn Heart and Vascular Institute
-
-
Georgia
-
Atlanta, Georgia, Соединенные Штаты, 30342
- Northside Hospital Heart & Vascular Institute
-
-
Illinois
-
Champaign, Illinois, Соединенные Штаты, 61820
- Presence Medical Center -- Christie Clinic
-
Chicago, Illinois, Соединенные Штаты, 60637
- University of Chicago
-
Rockford, Illinois, Соединенные Штаты, 61103
- Affiliated Surgeons of Rockford Memorial Hospital
-
-
Iowa
-
Iowa City, Iowa, Соединенные Штаты, 52242
- University of Iowa Hospital and Clinic
-
-
Massachusetts
-
Boston, Massachusetts, Соединенные Штаты, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Соединенные Штаты, 02111
- Tufts University Medical Center
-
Worcester, Massachusetts, Соединенные Штаты, 01655
- University of Massachusetts
-
-
Minnesota
-
Rochester, Minnesota, Соединенные Штаты, 55905
- Mayo Clinic
-
-
New York
-
Albany, New York, Соединенные Штаты, 12205
- Community Care (previously Albany Medical Center)
-
Buffalo, New York, Соединенные Штаты, 14203
- Buffalo General Medical Center
-
New York, New York, Соединенные Штаты, 10029
- Mount Sinai Medical Center
-
Rochester, New York, Соединенные Штаты, 14623
- University of Rochester -- Strong Memorial Hospital
-
Stony Brook, New York, Соединенные Штаты, 11794-8191
- Stony Brook Medical Center
-
-
North Carolina
-
Asheville, North Carolina, Соединенные Штаты, 28801
- Mission Hospital
-
Greenville, North Carolina, Соединенные Штаты, 27834
- East Carolina University / Pitt County Memorial Hospital
-
-
Ohio
-
Cleveland, Ohio, Соединенные Штаты, 44195
- Cleveland Clinic Foundation
-
Columbus, Ohio, Соединенные Штаты, 43210
- The Ohio State University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19140
- Temple University School of Medicine
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15232
- University of Pittsburgh Medical Center
-
York, Pennsylvania, Соединенные Штаты, 17403
- York Hospital
-
-
Rhode Island
-
Providence, Rhode Island, Соединенные Штаты, 02905
- Rhode Island Hospital
-
-
South Dakota
-
Sioux Falls, South Dakota, Соединенные Штаты, 57117
- Sanford University of South Dakota Medical Center
-
Sioux Falls, South Dakota, Соединенные Штаты, 51108
- North Central Heart (Avera Heart Hospital)
-
-
Virginia
-
Norfolk, Virginia, Соединенные Штаты, 23507
- Sentara Vascular Specialists
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Subject must be between the ages of 18 and 85
- Subject must be diagnosed with an infrarenal abdominal aortic aneurysm (AAA), with or without iliac artery involvement, by CT with contrast performed within 4 months of planned implant procedure
- Subject must have an infrarenal AAA that i. is > 4.5 cm in diameter for males, or > 4.0 cm in diameter for females, or ii. has increased in diameter by 0.5 cm in the last 6 months
- Subject must have i. infrarenal landing neck length of 10 mm or greater and an angle of less than 60 degrees relative to the long axis of the aneurysm (centerline at lowest renal to centerline at bifurcation) and a suprarenal neck angle of less than 45 degrees relative to the infrarenal neck axis and an outside diameter of 17 mm -32 mm, or ii. infrarenal landing neck length of 15 mm or greater and an angle of between 60 and 75 degrees relative to the long axis of the aneurysm and a suprarenal neck angle of less than 45 degrees relative to the infrarenal neck axis and an outside diameter of 16 mm-30 mm
- Subject's infrarenal landing neck must meet the vessel size requirements specified in the instructions for use (IFU) for the corresponding devices
- Subject must have lowest renal artery at least 9 cm from the aortic bifurcation
- Subject must have a distal iliac landing neck with i. an inside diameter of 8 mm - 13 mm and a length of at least 10 mm, or ii. an inside diameter of >13 mm - 20 mm and a length of at least 15 mm
- Subject's distal iliac landing neck must meet the vessel size requirements specified for the corresponding devices in the IFU
- Subject must have a total treatment length of at least 13 cm
- Subject must have a distal aortic diameter above the iliac bifurcation equal to or greater than 70% of the sum of the selected leg graft diameters that will pass through the same
- Subject must be willing and able to comply with 1-month, 6-month, and 12-month follow-up visits, as well as annual visits out to 5 years
- Subject must have adequate renal function to tolerate required follow-up contrast-enhanced CTs
- Subject must have adequate vascular access (e.g., patent iliac or femoral arteries) for introduction of the Navitel Delivery System, which is 18F (6 mm) or 19F (6.3 mm) outer diameter based on size of device used. Alternatively, subject's anatomy is suitable for creation of an iliac conduit.
- Subject or Legally Authorized Representative (LAR) must agree to sign Informed Consent Form
Exclusion Criteria:
- Subject is pregnant or lactating
- Subject has a dissection in abdominal aorta, ruptured aneurysm, or symptomatic aneurysm (as determined by treating physician)
- Subject has a patent inferior mesenteric artery that cannot be sacrificed and an occluded or stenotic celiac and/or superior mesenteric artery
- Implant procedure as planned does not allow for at least one patent hypogastric artery left intact, unless both are occluded on pre-op imaging
- Subject has a lesion that cannot be crossed by a guide wire
- Proximal neck cannot increase by more than 10% over 15mm or more than 7% over 10mm; i.e., no trapezoidal necks
- Subject has severe untreated coronary artery disease and/or unstable angina, significant areas of myocardium at risk (based on coronary angiogram or radionuclide scans), left ventricular ejection fraction < 20%, or recent diagnosis of Congestive Heart Failure (CHF)
- Subject has had a stroke or myocardial infarction within 6 months of the planned treatment date
- Subject has chronic obstructive pulmonary disease requiring routine need for oxygen therapy outside the hospital setting (e.g., daily or nightly home use)
- Subject has an active systemic infection or is suspected of having an active systemic infection (e.g.,AIDS/HIV, sepsis)
- Subject is morbidly obese (more than 100% over the ideal body weight or as defined by institutional standards) or has other clinical conditions that severely compromise or impair x-ray visualization of the aorta
- Subject has connective tissue disease (e.g., Marfan's syndrome)
- Subject has a mycotic aneurysm
- Subject has significant or circumferential calcification or mural thrombus in the proximal aortic neck
- Subject has significant or circumferential calcification or mural thrombus in the distal iliac landing zone
- Subject has significant or circumferential calcification or mural thrombus within the treatment length, which may adversely impact device patency
- Subject has a blood coagulation disorder or bleeding diathesis, the treatment for which cannot be suspended pre- and post-repair
- Subject is in acute or chronic renal failure (creatinine > 2.5 mg/dL) unless subject is stable on dialysis
- Subject has less than two-year life expectancy as evidenced by factors prohibiting major medical intervention (e.g., presence of malignancy, severe cardiopulmonary disease, etc.)
- Subject is participating in another research study, has received investigational study drug within 30 days of planned procedure, or has received an investigational device within one year of planned procedure
- Subject is confronted with other medical, social or psychological issues that the investigator believes may interfere with study treatment or follow-up. These reasons must be documented. An example may include adherence to a theological or personal doctrine with aversion or opposition to blood transfusion.
- Subject has had a prior AAA repair (endovascular or surgical)
- Subject has an untreatable allergy or sensitivity to contrast media, nitinol/nickel, or polyester
- Subject has undergone other major surgical or medical intervention within 45 days of the planned procedure or is planning to undergo other major surgical or medical intervention within 45 days post implantation (e.g., Coronary Artery Bypass Graft (CABG), organ transplantation, renal stenting, etc.)
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Н/Д
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Treovance
Subjects who receive the Treovance stent-graft |
Eligible subjects will be implanted with the Treovance Stent-Graft
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Primary Efficacy
Временное ограничение: 12 months
|
Successful aneurysm treatment which is a composite of the following: Technical success at the conclusion of the procedure; absence of aneurysm enlargement; absence of device-related complications (e.g., fracture, conversion to open surgical repair, etc.) |
12 months
|
|
Primary Safety
Временное ограничение: 30 days
|
The primary safety endpoint is composite major adverse event (MAE) rate (including myocardial infarction, stroke, respiratory failure, etc.) |
30 days
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Secondary Efficancy Endpoint -- Aneurysm-Related Mortality
Временное ограничение: Annually to 5-years; annually to 10-years (stent-fracture subjects only)
|
Aneurysm-related mortality at 12 month and annually to 5 years; annually to 10 years for subjects with Core Lab-confirmed fracture(s) |
Annually to 5-years; annually to 10-years (stent-fracture subjects only)
|
|
Secondary Efficacy Endpoint -- Technical Success
Временное ограничение: 30 days
|
Technical success at 30 days confirmed by an imaging modality (e.g. CT) |
30 days
|
|
Secondary Efficacy Endpoint -- Clinical Utility Measures
Временное ограничение: Perioperative/Periprocedural
|
Clinical utility measures (procedure time, time in the intensive care unit, length of hospital stay) |
Perioperative/Periprocedural
|
|
Secondary Efficacy Endpoint -- Secondary interventions
Временное ограничение: 30 days, 6 months, annually to 5-years; annually to 10-years (stent-fracture subjects only)
|
The secondary efficacy endpoint includes the rate of additional procedures performed to correct the original implant |
30 days, 6 months, annually to 5-years; annually to 10-years (stent-fracture subjects only)
|
|
Secondary Efficacy Endpoint -- Device-Related Events
Временное ограничение: 30 days, 6 months, and annually to 5-years; annually to 10-years (stent-fracture subjects only)
|
This endpoint includes the rate of events associated with the device. |
30 days, 6 months, and annually to 5-years; annually to 10-years (stent-fracture subjects only)
|
|
Secondary Safety Endpoint -- Individual Rate for Events included in the composite MAE
Временное ограничение: 30 days, 6 months, annually to 5 years
|
Secondary safety endpoints will include each individual rate for the adverse events included in the composite MAE at 30 days, 6 months, and annually to 5 years |
30 days, 6 months, annually to 5 years
|
|
Secondary Safety Endpoint -- Procedure-Related Complications
Временное ограничение: 30 days, 6 months, annually to 5 years
|
Procedure-related complications at 30 days, 6 months, 12 months, and annually to 5 years. |
30 days, 6 months, annually to 5 years
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Matthew Eagleton, MD, Cleveland Clinic Foundaton
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оцененный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- IP-0008-12
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .